Clinical Observation of Bifidobacteria Triple Viable Bacteria Combined with Infliximab in the Treatment of Moderate and Severe Ulcerative Colitis / 中国药房
China Pharmacy
; (12): 629-632, 2017.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-510327
Responsible library:
WPRO
ABSTRACT
OBJECTIVE:
To investigate therapeutic efficacy of bifidobacteria triple viable bacteria combined with infliximab in the treatment of moderate and severe ulcerative colitis(UC),and its effects on immune function.METHODS:
Seventy-two UC pa-tients were selected from gastroenterology department of the First Affiliated Hospital of Chongqing Medical University during Jun. 2009 to Jan. 2015. They was divided into single group and combination group according to therapy plan,with 36 cases in each group. Single group was given infliximab 5 mg/kg,ivgtt,on 0,2nd,6th,8th week. Combination group was additionally given bi-fidobacteria triple viable bacteria 420 mg,tid. Both groups were treated for consercutive 2 months. Clinical efficacies were com-pared between 2 groups as well as the levels of humoral immunity and T cell function. The occurrence of ADR was observed in 2 groups.RESULTS:
Clinical response rate of combination group was 86.11%,which was significantly higher than 52.78% of single group,with statistical significance (P0.05). After treatment,the levels of CD4+ and CD4+/CD8+ were significantly increased in both 2 groups,while the levels of CD8+,Th1 and Th2 were significantly decreased;the combination group was significantly better than the control group,with statistical significance (P0.05). After treatment,the levels of IgA and IgG were increased significantly in 2 groups,and the level of C3 was decreased significantly;the combination group was significantly better than the control group,with statistical significance (P0.05). There was no statistical significance in the incidence of ADR between 2 groups(P>0.05).CONCLUSIONS:
Bifidobacteria triple viable bacteria combined with infliximab shows significant therapeutic efficacy in the treatment of moderate and severe UC, and can significantly improve humoral immunity function and the recovery of T cell level,with good safety.
Full text:
Available
Database:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
China Pharmacy
Year:
2017
Document type:
Article